Nonalcoholic Fatty Liver Disease and Liver Transplantation

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 403-417

  Pham, Tuan ^a   Dick, Travis B ^b   Charlton, Michael R ^b  

^a UNIVERSITY OF UTAH   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Liver transplantation; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; The metabolic syndrome

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; EXTRA VIRGIN OLIVE OIL; GROWTH HORMONE; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; PLACEBO; ANTIDIABETIC AGENT; ANTIOXIDANT;

ANGIOCARDIOGRAPHY; BODY COMPOSITION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COFFEE; CONSENSUS DEVELOPMENT; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ELASTOGRAPHY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPOPITUITARISM; IMMUNOSUPPRESSIVE TREATMENT; LIPOTOXICITY; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW FAT DIET; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; TREATMENT INDICATION; WEIGHT GAIN; BODY MASS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIET; NON-ALCOHOLIC FATTY LIVER DISEASE; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

ANTIOXIDANTS; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR DISEASES; COMORBIDITY; DIET; HUMANS; HYPOGLYCEMIC AGENTS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; RECURRENCE; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE; VITAMIN E;

EID: 84962492077     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.014     Document Type: Review

References (90)

1. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
2. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
3. Byron D., Minuk G.Y. Clinical hepatology: a profile of an urban, hospital-based practice. Hepatology 1996, 24:813-815.
4. Bell B.P., Manos M.M., Zaman A., et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol 2008, 103:2727-2736.
5. Younossi Z.M., Stepanova M., Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver disease in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011, 9:524-530.
6. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
7. Fassio E., Alvarez E., Domínguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40:820-826.
8. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
9. Haflidadottir S., Jonasson J.G., Norland H., et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014, 14:166.
10. Onnerhag K., Nilsson P.M., Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol 2014, 49:1111-1118.
11. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
12. Sanyal A.J., Contos M.J., Sterling R.K., et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003, 98:2064-2071.
13. Jin X., Chen Y.P., Yang Y.D., et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012, 7:e34198.
14. Strasberg S.M., Howard T.K., Molmenti E.P., et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994, 20:829-838.
15. Kim W.R., Smith J.M., Skeans M.A., et al. OPTN/SRTR 2012 Annual data report: liver. Am J Transplant 2014, 14(Suppl 1):69-96.
16. O'Leary J.G., Landaverge C., Jennings L., et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011, 9:700-704.
17. Berzigotti A., Garcia-Tsao G., Bosch J., et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011, 54:555-561.
18. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
19. Nair S., Verma S., Thuluvath P.J. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35:105-109.
20. Leonard J., Heimbach J.K., Malinchoc M., et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008, 8:667-672.
21. Hakeem A.R., Cockbain A.J., Raza S.S., et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver Transpl 2013, 19:551-562.
22. Hong H.C., Hwang S.Y., Choi H.Y., et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014, 59:1772-1778.
23. Kim T.N., Park M.S., Lim K.I., et al. Relationships between sarcopenic obesity and insulin resistance, Inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013, 78:525-532.
24. Tandon P., Ney M., Irwin I., et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012, 18:1209-1216.
25. Heuman D.M., Abou-Assi S.G., Habib A., et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004, 40:802-810.
26. Durand F., Buyse S., Francoz C., et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014, 60:1151-1157.
27. Englesebe M.J., Patel S.P., He K., et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010, 211:271-278.
28. Krell R.W., Kaul D.R., Martin A.R., et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013, 19:1396-1402.
29. Montano-Loza A.J., Meza-Junco J., Baracos V.E., et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014, 20:640-648.
30. Abellan van Kan G., Houles M., Vellas B. Identifying sarcopenia. Curr Opin Clin Nutr Metab Care 2012, 15:436-441.
31. Hayahi F., Matsumoto Y., Momoki C., et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res 2013, 43:1264-1275.
32. Alvares-da-Silva M.R., Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005, 21:113-117.
33. Figueiredo F., Dickson E.R., Pasha T.M., et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl 2000, 6:575-581.
34. Tsien C., Shah S.N., McCullough A.J., et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol 2013, 25:85-93.
35. Toshikuni N., Arisawa T., Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol 2014, 20:7286-7297.
36. Musso G., Gambino R., Tabibian J.H., et al. Association of non-alcoholic fatty liver disease chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014, 11:e1001680.
37. Singal A.K., Salameh H., Kuo Y.F., et al. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014, 98:216-221.
38. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002, 35:1179-1185.
39. Giusto M., Berenquer M., Merkel C., et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation 2013, 95:1148-1153.
40. Houlihan D.D., Armstrong M.J., Davidov Y., et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?. Liver Transpl 2011, 17:1292-1298.
41. Nadim M.K., Sung R.S., Davis C.L., et al. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 2012, 12:2901-2908.
42. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367:20-29.
43. Mindikoglu A.L., Dowling T.C., Weir M.R., et al. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology 2014, 59:1532-1542.
44. De Souza V., Hadj-Aissa A., Dolomanova O., et al. Creatinine- versus cystatin C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014, 59:1522-1531.
45. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
46. Targher G., Bertolini L., Padovani R., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010, 53:713-718.
47. Oni E.T., Agatston A.S., Blaha M.J., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013, 230:258-267.
48. Harrinstein M.E., Flaherty J.D., Ansari A.H., et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 2008, 8:1523-1528.
49. Davidson C.J., Gheorghiade M.I., Flaherty J.D., et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 2002, 89:359-360.
50. Rubin D.A., Schulman D.S., Edwards T.D., et al. Myocardial ischemia after orthotopic liver transplantation. Am J Cardiol 1994, 74:53-56.
51. Raval Z., Harrinstein M.E., Skaro A.I., et al. Cardiovascular risk assessment of the liver transplant candidate. Cardiology 2011, 58:223-231.
52. Lentine K.L., Costa S.P., Weir M.R., et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates. J Am Coll Cardiol 2012, 60:434-480.
53. Cross E., Watt K.D., Pedersen R., et al. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl 2011, 17:23-31.
54. Heuer M., Kaiser G.M., Kahraman A., et al. Liver transplantation in nonalcoholic steatohepatitis is associated with mortality and post-transplant complications: a single-center experience. Digestion 2012, 86:107-113.
55. Barritt A.S., Dellon E.S., Kozlowski T., et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol 2011, 45:372-378.
56. Bhagat V., Mindikoglu A.L., Nudo C.G., et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009, 15:1814-1820.
57. VanWagner L.B., Bhave M., Te H.S., et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012, 56:1741-1750.
58. Quillin R.C., Wilson G.C., Sutton J.M., et al. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation. Surgery 2014, 156:1049-1056.
59. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18:29-37.
60. Maor-Kendler Y., Batts K.P., Burgart L.J., et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000, 70:292-297.
61. Dumortier J., Giostra E., Belbouab S., et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol 2010, 105:613-620.
62. Singal A.W., Watt K.D., Heimbach J.H., et al. Recurrence of metabolic syndrome and non-alcoholic steatohepatitis after liver transplantation - a comparative analysis. Hepatology 2012, 53(Suppl):636.
63. Loomba R., Wolfson T., Ang B., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014, 60:1920-1928.
64. Loomba R., Sirlin C.B., Ang B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015, 61:1239-1250.
65. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
66. Vajro P., Fontanella A., Perna C., et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994, 125:239-241.
67. Drenick E.J., Simmons F., Murphy J.F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970, 282:829-834.
68. Hickman I.J., Jonsson J.R., Prins J.B., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.
69. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396-1402.
70. Lin H.Z., Yang S.Q., Chuckaree C., et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
71. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
72. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
73. Mari M., Caballero F., Colell A., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006, 4:185-198.
74. Caballero F., Fernandez A., Matías N., et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem 2010, 285:18528-18536.
75. Mari M., Morales A., Colell A., et al. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009, 11:2685-2700.
76. Mari M., Colell A., Morales A., et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008, 134:1507-1520.
77. Charlton M., Krishnan A., Viker K., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011, 301:G825-G834.
78. Wouters K., van Gorp P.J., Bieghs V., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
79. Freedman N.D., Park Y., Abnet C.C., et al. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012, 366:1891-1904.
80. Anty R., Marjoux S., Iannelli A., et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012, 57:1090-1096.
81. Modi A.A., Feld J.J., Park Y., et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010, 51:201-209.
82. Molloy J.W., Calcagno C.J., Williams C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012, 55:429-436.
83. Saab S., Mallam D., Cox G.A., et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014, 34:495-504.
84. Kalthoff S., Ehmer U., Freiberg N., et al. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010, 139:1699-1710.
85. Gressner O.A., Lahme B., Rehbein K., et al. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol 2008, 49:758-767.
86. Shim S.G., Jun D.W., Kim E.K., et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013, 28:1877-1884.
87. Estruch R., Ros E., Salas-Salvadó J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013, 368:1279-1290.
88. Buettner R., Ascher M., Gäbele E., et al. Olive oil attenuates the cholesterol-induced development of nonalcoholic steatohepatitis despite increased insulin resistance in a rodent model. Horm Metab Res 2013, 45:795-801.
89. Kruse M., von Loeffelholz C., Hoffmann D., et al. Dietary rapeseed/canola-oil supplementation reduces serum lipids and liver enzymes and alters postprandial inflammatory responses in adipose tissue compared to olive-oil supplementation in obese men. Mol Nutr Food Res 2015, 59:507-519.
90. Hernandez R., Martinez-Lara E., Cañuelo A., et al. Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells. World J Gastroenterol 2005, 11:7480-7485.